Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study

December 10, 2013 • 8:40 AM EST

Tonix Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

November 26, 2013 • 8:40 AM EST

Tonix Pharmaceuticals to Present at the LD Micro Conference

November 21, 2013 • 9:05 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2013 Financial Results

November 13, 2013 • 4:05 PM EST

Tonix Pharmaceuticals Partners With the American Chronic Pain Association to Help Raise Awareness About Fibromyalgia

October 24, 2013 • 8:45 AM EDT

Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013

October 11, 2013 • 9:27 AM EDT

Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients

September 16, 2013 • 8:01 AM EDT

Tonix Pharmaceuticals to Present at the First Global Life Sciences Conference in Warsaw, Poland on September 17, 2013

September 12, 2013 • 8:00 AM EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 9, 2013

September 4, 2013 • 8:00 AM EDT

Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome

August 19, 2013 • 8:00 AM EDT

Show All

News / Press Releases : Press Releases